Cibc World Markets Corp Has $11.61 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Cibc World Markets Corp raised its position in Zoetis Inc. (NYSE:ZTS) by 15.5% during the fourth quarter, Holdings Channel reports. The firm owned 71,255 shares of the company’s stock after purchasing an additional 9,574 shares during the period. Cibc World Markets Corp’s holdings in Zoetis were worth $11,610,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Polen Capital Management LLC increased its stake in shares of Zoetis by 17.5% in the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock valued at $1,219,237,000 after acquiring an additional 1,116,541 shares in the last quarter. Arbor Capital Management Inc. ADV grew its stake in shares of Zoetis by 7.3% in the 4th quarter. Arbor Capital Management Inc. ADV now owns 5,806 shares of the company’s stock worth $986,000 after acquiring an additional 395 shares in the last quarter. Signature Wealth Management Group grew its stake in shares of Zoetis by 9.0% in the 4th quarter. Signature Wealth Management Group now owns 9,519 shares of the company’s stock worth $1,551,000 after acquiring an additional 784 shares in the last quarter. SlateStone Wealth LLC boosted its holdings in shares of Zoetis by 3.3% in the 4th quarter. SlateStone Wealth LLC now owns 26,191 shares of the company’s stock worth $4,267,000 after buying an additional 834 shares during the last quarter. Finally, First National Advisers LLC boosted its holdings in shares of Zoetis by 4.3% in the 4th quarter. First National Advisers LLC now owns 28,285 shares of the company’s stock worth $4,609,000 after buying an additional 1,176 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,862 shares of company stock worth $312,254. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ZTS shares. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Piper Sandler boosted their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. Finally, StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $215.90.

Zoetis Trading Up 2.6 %

Shares of ZTS opened at $165.39 on Tuesday. The business’s 50-day moving average price is $166.82 and its 200-day moving average price is $175.97. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The stock has a market cap of $74.06 billion, a PE ratio of 30.24, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.21%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.